<DOC>
	<DOC>NCT00076973</DOC>
	<brief_summary>The purpose of this study is to look at whether an investigational drug can treat the breathing symptoms of RSV bronchiolitis in children 3 to 24 months of age.</brief_summary>
	<brief_title>An Investigational Drug Study to Treat Respiratory Symptoms Associated With Respiratory Syncytial Virus (RSV) Bronchiolitis (0476-272)</brief_title>
	<detailed_description />
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Signs and Symptoms, Respiratory</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Hospitalized or in an urgent/emergentcare setting at least 24 hours for a first or second episode of RSVinduced bronchiolitis. Approximately twenty percent of patients will be allowed in the study with a stay of less than 24 hours but need to meet a minimum predefined Respiratory Severity Score as required by the study. Asthma or other wheezing disorder. The Primary Investigator will evaluate whether there are other reasons why a child may not participate.</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>RSV Bronchiolitis</keyword>
</DOC>